ArticleCancer immunology, immunotherapy : CII2026

A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia.

Marina Konopleva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.